Loading…

Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients

Saved in:

Bibliographic Details
Published in:	Leukemia & lymphoma 2023-01, Vol.64 (2), p.478-482
Main Authors:	Kutsch, Nadine, Holmes, Emily Eva, Robrecht, Sandra, Schüler, Gudrun, Vehling-Kaiser, Ursula, Decker, Thomas, Müller-Hagen, Sigrun, Heinisch, Karin, Böttcher, Sebastian, Ritgen, Matthias, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Fink, Anna Maria, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, Wendtner, Clemens-Martin
Format:	Article
Language:	English
Subjects:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Bendamustine Hydrochloride - adverse effects Cyclophosphamide - adverse effects Humans Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!